Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights rapid therapeutic progress and mechanistic insights with direct translational potential. A phase 3 trial demonstrates robust blood-pressure lowering from the aldosterone synthase inhibitor baxdrostat in resistant hypertension. Human pluripotent stem cell–derived adrenal organoids map prenatal zonation and model NR0B1-related adrenal hypoplasia, advancing regenerative and disease-model platforms. Mechanistic work links branched-chain α-ketoacids to
Summary
This week’s endocrinology literature highlights rapid therapeutic progress and mechanistic insights with direct translational potential. A phase 3 trial demonstrates robust blood-pressure lowering from the aldosterone synthase inhibitor baxdrostat in resistant hypertension. Human pluripotent stem cell–derived adrenal organoids map prenatal zonation and model NR0B1-related adrenal hypoplasia, advancing regenerative and disease-model platforms. Mechanistic work links branched-chain α-ketoacids to β-cell failure via LDHA reactivation, opening a novel targetable axis for diabetes.
Selected Articles
1. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
In patients with resistant hypertension on ≥3 antihypertensives, baxdrostat (aldosterone synthase inhibitor) reduced 24-h ambulatory systolic blood pressure by a placebo-corrected −14.0 mm Hg at 12 weeks. The trial was international, phase 3, double-blind with ABPM primary endpoint; hyperkalemia occurred in a minority (confirmed K+>6 mmol/L in 3%).
Impact: Demonstrates robust, clinically meaningful BP lowering by targeting aldosterone synthesis in a phase 3 RCT for resistant hypertension—addresses a major unmet need and may change add-on therapy choices.
Clinical Implications: Baxdrostat could become an important add-on for resistant hypertension pending longer-term outcomes; routine potassium monitoring will be essential to manage hyperkalemia risk.
Key Findings
- Placebo-corrected change in 24-h ambulatory SBP at 12 weeks: −14.0 mm Hg (95% CI −17.2 to −10.8; p<0.0001).
- Within-group LS mean change: −16.6 mm Hg with baxdrostat vs −2.6 mm Hg with placebo.
- Adverse events more frequent with baxdrostat (52% vs 37%); confirmed K+ >6 mmol/L in 3%.
2. Modeling human prenatal adrenocortical functional zonation dynamics from pluripotent stem cells.
A human pluripotent stem cell-derived adrenal organoid system recreated capsule-to-core zonation driven by RSPO3/WNT and ACTH, differentiated cortisol- and androgen-producing zones, and modeled NR0B1 loss causing X-linked adrenal hypoplasia congenita. Co-implantation reconstituted ACTH-responsive zonation in vivo, providing a platform for regenerative strategies and disease modeling.
Impact: Provides a mechanistically detailed human model of adrenal development with in vivo reconstitution and genetic disease modeling (NR0B1), enabling translational work in regenerative therapy and pathway-targeted screening.
Clinical Implications: Foundation for regenerative approaches to adrenal insufficiency, and an experimental human platform to screen modulators of WNT/RSPO3–ACTH signaling or test gene/cell therapies for congenital adrenal disorders.
Key Findings
- PSC-derived organoids recapitulated capsule-to-core zonation with RSPO3/WNT specifying definitive zone progenitors.
- Under RSPO3 and ACTH, progenitors formed cortisol-producing transitional and androgen-producing fetal zones.
- NR0B1 loss impaired definitive zone specification and induced primordium-to-fetal zone conversion, modeling X-linked adrenal hypoplasia.
3. Branched-chain α-keto acids impair glucose-stimulated insulin secretion in pancreatic β-cells under diabetes by reactivating the LDHA-lactate axis.
Using human islets, mouse models, and β-cell genetics, the study shows branched-chain α-ketoacids (BCKAs) directly bind and reactivate LDHA, diverting β-cell glucose metabolism toward lactate and suppressing glucose-stimulated insulin secretion. Lowering BCKAs or ablating β-cell LDHA rescued GSIS and improved glucose tolerance in models, identifying a druggable BCKA–LDHA axis.
Impact: Identifies a novel, targetable mechanistic link between amino-acid dysmetabolism and β-cell failure (BCKA–LDHA), challenging existing paradigms and offering new translational therapeutic opportunities for diabetes.
Clinical Implications: Strategies to lower circulating BCKAs or inhibit LDHA activity could restore β-cell function; dietary and pharmacologic interventions targeting BCAA/BCKA metabolism deserve translational evaluation.
Key Findings
- BCKAs inhibited GSIS across human and mouse islets and correlated inversely with insulin secretory capacity in diabetic humans.
- BCKAs directly bound LDHA, promoted dimerization, and reactivated the LDHA–lactate pathway, diverting glucose from the TCA cycle.
- β-cell-specific LDHA deletion rescued GSIS and glucose tolerance in BCKA-fed mice; lowering BCKAs improved GSIS in diabetic mice.